Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia

References

• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–464.
   PubMed Web of Science ®Google Scholar
• Ballman KV. Biomarker: predictive or prognostic? J Clin Oncol. 2015;33:3968–3971.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood. 2014;124:3345–3355.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119:332–341.
   PubMed Web of Science ®Google Scholar
• Hourigan CS, Gale RP, Gormley NJ, et al. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482–1490.
   PubMed Web of Science ®Google Scholar
• Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–336.
   PubMed Web of Science ®Google Scholar
• Inaba H, Coustan-Smith E, Cao X, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012;30:3625–3632.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Review article. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–448.
   Google Scholar
• Ossenkoppele G, Schuurhuis GJ. MRD in AML: does it already guide therapy decision-making? Hematol. Am Soc Hematol Educ Progr. 2016;2016:356–365.
   PubMedGoogle Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European leukemianet study. J Clin Oncol. 2009;27:5195–5201.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: consensus document from ELN MRD working party. Blood. 2018. blood-2017-09-801498.
   PubMedGoogle Scholar
• Pastore F, Levine RL. Next-generation sequencing and detection of minimal residual disease in acute myeloid leukemia ready for clinical practice? JAMA. 2015;24–26.
   Google Scholar
• Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314:811.
   PubMed Web of Science ®Google Scholar
• Getta BM, Devlin SM, Levine RL, et al. Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol Blood Marrow Transplant. 2017;23:1064–1071.
   PubMed Web of Science ®Google Scholar
• Terwijn M, Zeijlemaker W, Kelder A, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:7–9.
   Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11:543–552.
   PubMed Web of Science ®Google Scholar
• Terwijn M, van Putten WLJ, Kelder A, et al. High Prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–3897.
   PubMed Web of Science ®Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–433.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–2221.
   PubMed Web of Science ®Google Scholar
• Venditti A, Piciocchi A, Candoni A, et al. MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia: results of the AML1310 trial of the GIMEMA group. 22Th EHA Congr. Haematologica. 2017;102(s2):S111.
   Google Scholar
• Zhu -H-H, Zhang X-H, Qin Y-Z, et al. MRD-directed risk-stratification treatment may improve outcome of t (8;21) AML in the first complete remission: results from AML05 multicenter trial. Blood. 2013;121:4056–4063.
   PubMed Web of Science ®Google Scholar
• Balsat M, Renneville A, Thomas X, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the acute leukemia French association group. J Clin Oncol. 2017;35:185–193.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29:137–144.
   PubMed Web of Science ®Google Scholar
• Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865–873.
   PubMed Web of Science ®Google Scholar
• Walter RB, Buckley SA, Pagel JM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813–1821.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Piciocchi A, et al. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplant. 2017;52:473–475.
   PubMed Web of Science ®Google Scholar
• Leung W, Pui C-H, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood. 2012;120:468–472.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Walter RB. Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission? Curr Opin Hematol. 2017;24:132–138.
   PubMed Web of Science ®Google Scholar
• Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–4131.
   PubMed Web of Science ®Google Scholar
• Bachas C, Schuurhuis GJ, Assaraf YG, et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia. 2012;26:1313–1320.
   PubMed Web of Science ®Google Scholar
• Kotrova M, Trka J, Kneba M, et al. Is next-generation Sequencing the way to go for residual disease monitoring in acute lymphoblastic leukemia? Mol Diagn Ther. 2017;21:481–492.
   PubMed Web of Science ®Google Scholar
• Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–2103.
   PubMed Web of Science ®Google Scholar